# Entrada Therapeutics to Present at Upcoming Investor Conferences Canonical URL: https://biopharmsignal.com/news/TRDA/entrada-therapeutics-to-present-at-upcoming-investor-conferences-14ce009b Ticker: TRDA Company: Entrada Therapeutics Source: Entrada Therapeutics Published: 2026-02-04 12:00 EST ## Summary Entrada Therapeutics announces that the Company will participate in two upcoming investor conferences.... ## Article Body Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the Company will participate in two upcoming investor conferences. Guggenheim Emerging Outlook: Biotech Summit 2026 Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Wednesday, February 11, 2026, at 4:00 p.m. Eastern Time in New York, NY. TD Cowen 46 th Annual Health Care Conference Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Tuesday, March 3, 2026, at 2:30 p.m. Eastern Time in Boston, MA. Live webcasts will be available on the Investor Relations section of the Company’s website at www.entradatx.com . Replays will be available on the Entrada website for 90 days following the events. About Entrada Therapeutics Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Entrada is advancing a robust development portfolio of RNA- and protein-based programs for the potential treatment of neuromuscular, ocular and other diseases, leveraging next-generation EEVs, novel oligonucleotide sequences and an advanced protein engineering platform. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. For more information about Entrada, please visit our website, www.entradatx.com , and follow us on LinkedIn . Investor Contact Karla MacDonald Chief Corporate Affairs Officer kmacdonald@entradatx.com Media Contact Megan Prock McGrath CTD Comms, LLC megan@ctdcomms.com ## Recent Company News - 2026-06-02 11:00 EST — [Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study](https://biopharmsignal.com/news/TRDA/independent-safety-data-monitoring-committee-recommends-initiation-of-cohort-2-a-2a48ec2d) — Source: Entrada Therapeutics - 2026-06-01 20:30 EST — [Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/TRDA/entrada-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635--4f6f3117) — Source: Entrada Therapeutics - 2026-05-07 11:10 EST — [Entrada Therapeutics Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/TRDA/entrada-therapeutics-reports-first-quarter-2026-financial-results-4b45cf5b) — Source: Entrada Therapeutics - 2026-05-07 11:00 EST — [Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study](https://biopharmsignal.com/news/TRDA/entrada-therapeutics-announces-positive-topline-results-from-cohort-1-of-partici-8bfbed27) — Source: Entrada Therapeutics - 2026-05-06 20:30 EST — [Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026](https://biopharmsignal.com/news/TRDA/entrada-therapeutics-to-announce-topline-results-from-cohort-1-of-participants-w-c8a2a4f7) — Source: Entrada Therapeutics ## Related News - 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9) - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)